Over the past two decades, significant progress in understanding of the pathogenesis of type
2 chronic inflammatory diseases has enabled the identification of compounds for more than …

Type 2 inflammation is characterized by overexpression and heightened activity of type 2
cytokines, mediators and cells that drive neuroimmune activation and sensitization to …

Background Lebrikizumab is a novel, high-affinity monoclonal antibody that selectively binds
to interleukin (IL)-13. Objectives To evaluate the efficacy and safety of lebrikizumab …

ABSTRACT The 'Antibodies to Watch'article series provides an annual summary of
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …

Considering the role of epidermal keratinocytes, they occupy more than 90% of the
epidermis, form a physical barrier, and also function as innate immune barrier. For example …

Atopic dermatitis represents a complex and multidimensional interaction that represents
potential fields of preventive and therapeutic management. In addition to the treatment …

The US Food and Drug Administration approval of dupilumab for moderate-to-severe atopic
dermatitis shifted the paradigm from use of broad, systemic immunosuppressants to a safer …

Atopic dermatitis (AD) represents the most common skin disease characterized by
heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on developing the …

Atopic dermatitis (AD) is a common, heterogeneous, inflammatory skin disorder
characterized by chronic or relapsing eczematous lesions with intense pruritus and …